Compare VTVT & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTVT | ACU |
|---|---|---|
| Founded | 2015 | 1867 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 160.6M |
| IPO Year | 2015 | 1994 |
| Metric | VTVT | ACU |
|---|---|---|
| Price | $33.17 | $42.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $53.00 | $50.00 |
| AVG Volume (30 Days) | ★ 29.7K | 19.2K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 1.63 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $196,541,816.00 |
| Revenue This Year | N/A | $5.67 |
| Revenue Next Year | N/A | $5.25 |
| P/E Ratio | ★ N/A | $175.67 |
| Revenue Growth | N/A | ★ 1.05 |
| 52 Week Low | $14.00 | $35.50 |
| 52 Week High | $44.00 | $47.31 |
| Indicator | VTVT | ACU |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 50.41 |
| Support Level | $30.09 | $40.54 |
| Resistance Level | $33.11 | $43.18 |
| Average True Range (ATR) | 2.60 | 1.39 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 32.56 | 73.25 |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.